Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity (Study ID: NN9838-4608)

Is this Study for You?

Let's Get Started!


Participants will be randomly assigned to one of four treatment options (CagriSema, or Cagrilintide alone, Semaglutide alone, or placebo) and will receive monthly dietary counseling during the 75 week main study.




Participants must be: -18 years or older -Have a BMI of 30 or greater (or a BMI of 27 or greater with high blood pressure, high cholesterol, sleep apnea or cardiovascular disease) -NOT have type 1 or 2 diabetes

Type of Study



Anschutz Health and Wellness
Outpatient CTRC

Principal Investigator
Photograph of Daniel Bessesen,  MD

Daniel Bessesen, MD

Study ID

Protocol Number: 22-1393

More information available at NCT05567796

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers